Advertisement
Advertisement
Trending on OncLive
1
frontMIND: Phase 3 Study of Tafasitamab Plus Lenalidomide and R-CHOP for Patients With Newly Diagnosed Diffuse Large B-cell Lymphoma
2
A Randomized Phase III Study Evaluating Izalontamab Brengitecan (Iza-bren) Versus Physician’s Choice of Chemotherapy in Patients with Unresectable Locally Advanced or Metastatic Triple-Negative Breast Cancer (TNBC)
3
Dr Morgans on the Cognitive Effects of Darolutamide Vs Enzalutamide in Prostate Cancer
4